Company Encyclopedia
View More
name
Heron Therap
HRTX.US
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults.
1.946 T
HRTX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking127/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE82.34%A
    • Profit Margin-8.75%D
    • Gross Margin59.74%A
  • Growth ScoreB
    • Revenue YoY12.60%B
    • Net Profit YoY51.45%B
    • Total Assets YoY12.76%B
    • Net Assets YoY137.21%A
  • Cash ScoreC
    • Cash Flow Margin-1142.27%E
    • OCF YoY12.60%B
  • Operating ScoreB
    • Turnover0.66B
  • Debt ScoreE
    • Gearing Ratio94.02%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Rating of "Hold" by Brokerages

    Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a consensus rating of "Hold" from five brokerages. One analyst rated it as a sell, one as hold, and three as buy, with an average 12-month price target of $4.50. Recent insider transactions include major shareholder Rubric Capital Management acquiring 2.39 million shares and Director Adam Morgan purchasing 1.77 million shares, both at $1.50 per share. The stock is currently trading at $1.14, with a market cap of $208.98 million and a P/E ratio of -57.00.

    Market Beat·
    US
    HRTX
    +3.15%
    Market Beat·
    US
    HRTX
    +3.15%

    Heron Therapeutics’ Earnings Call: Growth Amid Challenges

    Heron Therapeutics Inc. reported mixed results in its earnings call, showcasing strong growth in ZYNRELEF and APONVIE sales, with net revenues of $38.2 million for the quarter. Despite a net loss of $17.5 million due to debt extinguishment and a 32% decline in SUSTOL sales, the company successfully completed financing, allowing a focus on commercial execution. A permanent J-code for ZYNRELEF is expected to enhance reimbursement processes. The company projects net revenue between $153 million and $163 million for the fiscal year, indicating optimism for future growth despite current challenges.

    Tip Ranks·
    US
    HRTX
    +3.15%
    Tip Ranks·
    US
    HRTX
    +3.15%

    Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth

    Heron Therapeutics is experiencing positive growth, particularly with its products Zynrelef and Aponvie. Zynrelef has seen a 49% year-over-year revenue increase due to heightened demand and improved reimbursement access. Aponvie's growth is supported by a newly trained sales team. Despite some challenges in the oncology sector, the overall outlook remains optimistic, with strategic investments and potential inclusion in clinical guidelines. Needham has maintained a Buy rating on the stock with a $3.00 price target.

    Tip Ranks·
    US
    HRTX
    +3.15%
    Tip Ranks·
    US
    HRTX
    +3.15%

    Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics

    Brandon Folkes has assigned a Buy rating for Heron Therapeutics, citing promising growth driven by their third-quarter earnings report. Key products Zynrelef and Aponvie are entering a critical growth phase, with Zynrelef benefiting from a new permanent J-code that simplifies reimbursement. Year-over-year demand for Zynrelef is strong, supported by strategic initiatives like enhanced distributor incentives. Aponvie's sales growth is bolstered by a dedicated sales team, while stable Cinvanti revenues further indicate a positive outlook for the company.

    Tip Ranks·
    US
    HRTX
    +3.15%
    Tip Ranks·
    US
    HRTX
    +3.15%

    Heron Therap | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 38.21 M

    LB filings·
    US
    HRTX
    +3.15%
    LB filings·
    US
    HRTX
    +3.15%
    © 2025 Longbridge｜Disclaimer